Compare Eli Lilly And Co (LLY) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Lowe`s Companies Inc — how do they compare? Eli Lilly And Co trades at $1,176.52 (market cap $1.04T), while Lowe`s Companies Inc trades at $186.23 (market cap $105.96B). The key difference: Eli Lilly And Co is far larger — about 9.8× Lowe`s Companies Inc's market cap, and Lowe`s Companies Inc pays the higher dividend (2.65%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Lowe`s Companies Inc for 98 Days on average.
| LLY | LOW | |
|---|---|---|
Market Cap | $1.04T | $105.96B |
Volume | 3,064,878 | 4,039,547 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $287.39 |
52-Week Low | $799.57 | $179.50 |
Typical Hold Time | 93 Days | 98 Days |
Enterprise Value | $1.09T | $144.81B |
Dividend Yield | 0.59% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Lowe's (LOW) trades at $185.27, up 2.05% today, but faces a bearish technical signal with key resistance at $191. The company reported Q2 2026 EPS of $4.40, beating estimates, yet revenue has declined from $96.2B in 2022 to $83.7B in 2025. Analysts maintain a strong buy consensus with a $244.09 price target, citing value despite industry headwinds. Recent news highlights drone delivery innovation with DoorDash and Alphabet's Wing, aiming to enhance customer convenience.
LOW presents a value opportunity with a P/E of 15.96 and bullish analyst sentiment, but risks include a challenging housing market and declining revenue trends. The stock's upside hinges on execution of new initiatives and economic recovery in home improvement spending, with near-term volatility expected amid macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
